Recent News

• 08.06.2026 - Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
• 07.24.2026 - Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
• 06.16.2026 - Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD
• 06.01.2026 - Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
• 05.28.2026 - Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
• 05.26.2026 - Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
• 05.15.2026 - Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
• 04.23.2026 - Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
• 04.22.2026 - Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
• 04.21.2026 - Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Recent Filings

• 07.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.24.2026 - 8-K Current report
• 07.24.2026 - 8-K Current report
• 07.24.2026 - EX-99.1 EX-99.1
• 07.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.21.2026 - EFFECT Notice of Effectiveness
• 07.21.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 07.17.2026 - S-3 Registration statement under Securities Act of 1933
• 07.16.2026 - 8-K Current report